All In Biotech

Drug Trial Radar · NCT04419363

Burosumab in Children and Adolescents With X-linked Hypophosphatemia

12-months of Treatment With Burosumab in Children and Adolescents With X-linked Hypophosphatemia: a Prospective Longitudinal Cohort Study

Last checked: Nov 20, 2026Latest source record: Jun 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

57

Planned (sponsor's estimate)

Start

Mar 18, 2018

Primary completion

Mar 20, 2019

Study completion Sep 16, 2022

Sponsor

Lead sponsor
Bicetre HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this prospective longitudinal cohort study we studied the efficacy and safety of burosumab in real-clinical practice for \<13- and \>13-years old children affected with X-linked hypophosphatemia. 57 children with XLH were switched from conventional treatment to burosumab. After 12 months we assessed the efficacy and safety of treatment with burosumab on the whole cohort and separately on the cohort of \>13-years old adolescents.

Conditions

  • Rare Diseases
  • X-linked Hypophosphatemia

Interventions

  • Burosumab InjectionDrug

    Children affected with X-linked hypophosphatemia were switched from conventional therapy to burosumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiological changes in rachitic lesions evaluated with knee MRITime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Bicetre

    Le Kremlin-Bicêtre, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.